humanova and Bayer enter into a strategic partnership to expand access to oncology therapies in Brazil
humanova strengthens its oncology portfolio following the execution of an agreement with Bayer, a leading pharmaceutical company, for the commercialization, distribution, and medical promotion in Brazil of two therapies: Nexavar® (sorafenib), indicated for liver, kidney, and thyroid cancer, and Stivarga® (regorafenib), for gastrointestinal tract cancers.
The transaction leverages the expertise of humanova’s Brazilian affiliate, Farmarin humanova, as well as its track record of more than 33 registered molecules across Latin America and Europe.
This agreement reflects a shared vision to combine Bayer’s scientific innovation with humanova’s strong presence in the institutional market in Brazil, expanding access to high-value oncology therapies for more patients.
André Luís Ramos Coutinho, Corporate Director of Oncology and Rare Diseases, highlighted that “our expectation is to strengthen the positioning of these treatments by combining the robustness of Bayer’s portfolio with our commercial execution capabilities.”
Meanwhile, Kauê Cunha, Commercial Excellence Director of Bayer’s pharmaceutical division in Brazil and Latin America, stated that “this agreement reinforces our strategy to maintain our internal efforts and investments in launches that reflect the most innovative developments in their respective areas, while, through such partnerships, we can continue investing in established brands that still have strong potential to positively impact patients’ lives.”
Bayer retains ownership of the product registrations and manufacturing, while Farmarin humanova will lead commercial distribution activities, joining efforts to maximize the value of these therapies and significantly improve patients’ lives.
About Bayer
Bayer is a global company with core competencies in the life science fields of healthcare and nutrition. In line with its mission, “Health for all, hunger for none,” the company’s products and services are designed to help people and the planet thrive, supporting efforts to address the challenges of a growing and aging global population.
Bayer is committed to driving sustainable development and generating a positive impact through its activities. At the same time, the Group aims to enhance its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability, and quality worldwide.
In fiscal year 2025, the Group employed approximately 88,000 people and generated sales of €45.6 billion. Research and development expenses amounted to €5.8 billion. For more information, please visit www.bayer.com
About humanova
humanova is a global pharmaceutical corporation, headquartered in the United States, united by a shared purpose: to transform global health so that more people can build the future they aspire to. Through its international operations across nine countries in Latin America and Europe, the company develops, manufactures, and ensures access to high-quality medicines, available in more than 50 countries worldwide.
The corporation aspires to be a benchmark in the pharmaceutical industry—a brand committed to society, human-centered, and dedicated to supporting, caring for, and transforming the health of the people it interacts with every day.
Farmarin humanova in Brazil is part of the global holding humanova Lab Corporation.